Hidden Markov models are recurrent neural networks: A disease
  progression modeling application by Baucum, Matt et al.
Hidden Markov models are recurrent neural
networks: A disease progression modeling application
Matt Baucum
Industrial & Systems Engineering
University of Tennessee Knoxville
Knoxville, TN 37996
mbaucum1@vols.utk.edu
Anahita Khojandi
Industrial & Systems Engineering
University of Tennessee Knoxville
Knoxville, TN 37996
khojandi@utk.edu
Theodore Papamarkou
Computational Sciences and Engineering Division
Oak Ridge National Laboratory
Oak Ridge, TN 37831
papamarkout@ornl.gov
Abstract
Hidden Markov models (HMMs) are commonly used for sequential data modeling
when the true state of the system is not fully known. We formulate a special case
of recurrent neural networks (RNNs), which we name hidden Markov recurrent
neural networks (HMRNNs), and prove that each HMRNN has the same likelihood
function as a corresponding discrete-observation HMM. We experimentally validate
this theoretical result on synthetic datasets by showing that parameter estimates
from HMRNNs are numerically close to those obtained from HMMs via the
Baum-Welch algorithm. We demonstrate our method’s utility in a case study
on Alzheimer’s disease progression, in which we augment HMRNNs with other
predictive neural networks. The augmented HMRNN yields parameter estimates
that offer a novel clinical interpretation and fit the patient data better than HMM
parameter estimates from the Baum-Welch algorithm.
1 Introduction
Hidden Markov models (HMMs; [1]) are commonly used for modeling disease progression, because
they allow researchers to conceptualize complex (and noisy) clinical measurements as originating from
a smaller set of latent health states (typically discrete). Each latent health state is characterized by an
emission distribution that specifies the probabilities of each measurement/observation given that state.
This allows HMMs to explicitly account for uncertainty or measurement error, since the system’s true
state is not fully observable. Because of their intuitive parameter interpretations and flexibility, HMMs
have been used to model biomarker changes in HIV patients [2], Alzheimer’s disease progression [3],
breast cancer screening decisions [4], and patient response to blood anticoagulants [5].
For certain health applications, researchers may wish to integrate HMMs with other disease pro-
gression models and/or data sources. For instance, researchers in [6] jointly trained parameters for
a partially-observable Markov decision process and a reinforcement learning policy to maximize
patient returns. Other researchers have attempted to learn or initialize HMM parameters based on
additional sources of patient data; [7] presents a procedure for initializing HMM parameters from
limited information about patient health states, while [8] learned a cancer progression HMM where
the transition probabilities depend on patient-level covariates. Such HMM modifications typically
require multiple estimation steps (e.g., [8]) or changes to parameter interpretation (e.g., [6]). This
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is because the algorithm for fitting HMMs, the Baum-Welch algorithm [1], is strictly designed to
maximize the likelihood of a data sequence without consideration of additional covariates.
In this work, we introduce Hidden Markov Recurrent Neural Networks (HMRNNs) - neural networks
that mimic the computation of hidden Markov models while allowing for substantial modularity
with other predictive networks. Unlike past work combining neural networks and HMMs (e.g., [9]),
HMRNNs are not domain-specific, and are designed to maximize the most commonly-used HMM fit
criterion - the likelihood of the data given the parameters. In doing so, our primary contributions are
as follows: (1) We prove how recurrent neural networks (RNNs) can be formulated to optimize the
same likelihood function as HMMs, with parameters that can be interpreted as HMM parameters; (2)
We show how HMMs formulated as neural networks can easily ‘plug in’ to other neural networks,
allowing for one-step estimation of robust predictive models; (3) We demonstrate our model’s utility
in a disease progression application, in which it improves predictive accuracy and offers unique
parameter interpretations not afforded by simple HMMs.
2 Related work
There exists a limited but growing literature that explores the integration of HMMs and neural
networks, mostly with applications in speech analysis and handwriting recognition. [10], [11], and
[12] combined HMMs and neural networks for handwriting recognition. [10] used HMM outputs
as the inputs for a neural network to identify fraudulent signatures, while [12] used HMM outputs
as the targets for training a neural network to recognize cursive handwriting. In [11], researchers
combined HMM and RNN outputs to learn complementary text features. [13] jointly optimized an
HMM/neural network hybrid for speech recognition, with the neural network supplying the HMM
input sequences. [14] uses HMMs to interpret the hidden state representations from RNNs trained on
language data. Although this literature is somewhat related to our work, it does not focus on casting
HMMs as neural networks, the subject of our study.
A smaller number of studies have attempted to formally model HMMs in a neural network context.
Researchers in [15] proposed using neural networks to approximate Gaussian emission distributions
in HMMs; however, their method requires pre-training of the HMM and merely uses the neural
network to ‘refine’ the emission parameters. Similar to our work, [9] demonstrated how HMMs can
be reduced to recurrent neural networks for speech recognition, though it requires that neurons be
computed via products (rather than sums), which are not commonly used in modern neural networks.
Furthermore, the model in [9] maximizes the mutual information between observations and hidden
states; this is a commonly used criterion in speech recognition, but less common than likelihood
maximization in other domains (e.g., disease progression modeling). Lastly, [9] and [15] presented
only theoretical justification, with no empirical comparisons with the Baum-Welch algorithm. In
contrast with past work, we formulate an HMM that can be fully trained as a neural network, employs
widely-used neural network operations, maximizes the observed data’s likelihood, and compares
favorably to the Baum-Welch algorithm when tested on real-world datasets.
A limited number of studies have also explored connections between neural networks and Markov
models in the healthcare domain. For instance, [5] employed a discriminative hidden Markov model
to estimate ‘hidden states’ underlying patients’ ICU measurements, though these hidden states were
not mathematically equivalent to HMM latent states. In another study, [16] compared HMM and
neural network effectiveness in training a robotic surgery assistant. Both models were used to
recognize and predict surgeons’ movements, with the neural network offering increased accuracy and
the HMM offering reduced computational complexity. [17] proposed a generative neural network
for modeling ICU patient health. The model was used for training reinforcement learning treatment
policies, and was based on the core principles of HMMs. Although these studies showcase the of
value of pairing neural networks and Markov models in the healthcare domain, they differ from our
approach of directly formulating HMMs as neural networks, which maintains the interpretability of
HMMs while allowing for joint estimation of the HMM with other predictive models.
In summary, while these studies have shown the promise of incorporating elements of HMMs into deep
learning tasks, there are no existing methods for optimizing HMM log-likelihood in a neural network
context. Implementing HMMs as neural networks maintains their interpretability, while allowing
additional data sources (e.g., patient covariates) to steer model estimation to better-fitting solutions.
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and an Alzheimer’s disease progression case study of public clinical data. Finally, in Section 5 we
discuss the findings and future work.
3 Methods
In this section, we briefly review HMM preliminaries, formally define the HMRNN, and prove that it
optimizes the same likelihood function as a corresponding HMM.
3.1 HMM preliminaries
Formally, an HMM models a system over a given time horizon T , where the system occupies a hidden
state xt ∈ S = {1, 2, . . . , k} at any given time point t ∈ {0, 1, . . . , T}; that is, xt = i indicates that
the system is in the ith state at time t. For any state xt ∈ S and any time point t ∈ {0, 1, . . . , T},
the system emits an observation according to an emission distribution that is uniquely defined for
each state. We consider the case of categorical emission distributions, which are commonly used in
healthcare (e.g., [3, 18, 4, 19]). These systems emit one of c distinct observations at each time point;
that is, for any time t, we observe yt ∈ O, where |O| = c and O = {1, . . . , c}.
Thus, an HMM is uniquely defined by a k-length initial probability vector pi, k × k transition matrix
P , and k × c emission matrix Ψ. Entry i in the vector pi is the probability of starting in state i, row i
in the matrix P is the state transition probability distribution from state i, and row i of the matrix Ψ
is the emission distribution from state i.
HMMs are fit via the Baum-Welch algorithm, which identifies the parameters that (locally) maximize
the likelihood of the observed data [1]. The likelihood of an observation sequence y is a function of
an HMM’s initial state distribution (pi), transition probability matrix (P ), and emission matrix (Ψ)
[20]. Let diag(Ψi) be a k × k diagonal matrix with the ith column of Ψ as its entries - that is, the
probabilities of observation i from each of the k states. Therefore, we have
Pr(y|pi,P ,Ψ) = pi> · diag(Ψy0) · (
T∏
t=1
P · diag(Ψyt)) · 1k×1. (1)
3.2 Definition of hidden Markov recurrent neural networks (HMRNNs)
An HMRNN is a recurrent neural network whose parameters directly correspond to the initial state,
transition, and emission probabilities of an HMM. As such, training an HMRNN optimizes the joint
log-likelihood of the N T -length observation sequences given these parameters.
Definition 3.1. An HMRNN is a recurrent neural network with trainable parameters pi (a k-length
stochastic vector), P (a k × k stochastic matrix), and Ψ (a k × c stochastic matrix). It is trained
on T + 1 input matrices of size N × c, denoted by Yt for t ∈ {0, 1, . . . , T}, where the n-th row
of matrix Yt is a one-hot encoded vector of observation y
(n)
t for sequence n ∈ {1, . . . , N}. The
HMRNN consists of an inner block of hidden layers that is looped T +1 times (for t ∈ {0, 1, . . . , T}),
with each loop containing hidden layers h(t)1 , h
(t)
2 , and h
(t)
3 , and a c-length input layer h
(t)
y through
which the input matrix Yt enters the model. The HMRNN has a single output unit o(T ) whose value
is the joint negative log-likelihood of the N observation sequences under an HMM with parameters
pi, P , and Ψ; the summed value of o(T ) across all N observation sequences is also the loss which is
minimized through any neural network optimizer (e.g., gradient descent).
Layers h(t)1 , h
(t)
2 , h
(t)
3 , and o
(T ) are defined in the following equations. Note that the block matrix
in equation (3) is a c× (kc) block matrix of c 11×kvectors , arranged diagonally, while the block
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Figure 1: Structure of the hidden Markov recurrent neural network (HMRNN). Solid lines indicate
learned weights that correspond to HMM parameters; dotted lines indicate weights fixed to 1. The
inner block initializes with the initial state probabilities then mimics multiplication by Ψ; connections
between blocks mimic multiplication by P .
matrix in equation (4) is a (kc)× k row-wise concatenation of c k × k identity matrices.
h
(t)
1 =
{
pi>, t = 0,
h
(t−1)
3 P , t > 0.
(2)
h
(t)
2 = ReLu
(
h
(t)
1 [diag(Ψ1) . . . diag(Ψc)] + Yt
[
11×k . . . 01×k
. . . . . . . . .
01×k . . . 11×k
]
− 1n×(kc)
)
(3)
h
(t)
3 = h
(t)
2 [Ik . . . Ik]
> (4)
o(T ) = − log(h(t)3 1k×1). (5)
Fig. 1 outlines the structure of the HMRNN. Intuitively, operations within each recurrent block mimic
matrix multiplication by diag(Ψyt) (i.e., h
(t)
3 = h
(t)
1 diag(Ψyt)), while connections between blocks
mimic multiplication by P . In each block, layer h(t)1 contains k units that represent the probability of
being in each state 1–k, given all past observations. Layer h(t)2 , expands each unit in h
(t)
1 into c units
via connections with weights Ψi,j for i ∈ {1, . . . , k} and j ∈ {1, . . . , c}, resulting in k · c units; this
is equivalent to multiplying h(t)1 (in row-vector form) by a column-wise concatenation of diag(Ψj)
for j ∈ {1, . . . , c}. The resulting units represent the probabilities of all possible state/outcome
combinations at time t.
Layer h(t)2 takes two more inputs: A bias unit (set to −1), and Yt, a one-hot encoded n× c matrix of
data for time t, with each row a one-hot encoded vector of the observation for sequence n at time
t. Each column in Yt is connected to all units in h
(t)
2 that correspond to that column’s observation,
with connection weights set to 1. This is equivalent to multiplying Yt by a k × c block matrix of
c 11×kvectors, arranged diagonally. A ReLu activation is then applied to the layer; this leaves the
units that correspond to Yt unchanged, while all other units (i.e., probabilities for non-occurring
observations) are made negative by the−1 bias, then forced to zero through the ReLu activation. Thus,
layer h(t)2 identifies the joint probability of being in each state and observing Yt. Layer h
(t)
3 then
sums across all c units for each of the k states (all of which are zero except for those corresponding
to Yt), yielding k units; this is equivalent to multiplying h
(t)
2 by a row-wise concatenation of c k × k
identity matrices. The k units in layer h(t)3 now represent the probabilities of being in each state given
all previous observations and the observation at time t, i.e., h(t)3 = h
(t)
1 diag(Ψyt).
We then apply a fully-connected layer of weights to transform h(3)3 to h
(t+1)
1 , equivalent to matrix
multiplication by P , i.e., h(t+1)1 = h
(t)
3 P . Lastly, activations for h
(T )
3 are summed into unit o
(T )
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and subject to a negative logarithmic activation function, yielding the negative log-likelihood of the
data given the model’s parameters.
The HMRNN is a special case of an RNN, due to its time-dependent layers and shared weights
between time points. Note that its use of recurrent blocks (each of which containing three layers)
differs from many RNNs that use only a single layer at each time point; this distinction allows the
HMRNN to mimic HMM computations of an HMM at each time point.
3.3 Proof of HMM/HMRNN Equivalence
We now formally establish that the HMRNN’s output unit, o(T ), is the negative log-likelihood of an
observation sequence under an HMM with parameters pi, P , and Ψ. We prove this for the case of
N = 1 and drop notational dependence on n (i.e., we write y(1)t as yt), though extension to N > 1
is trivial since the log-likelihood of multiple independence sequences is simply the sum of their
individual log-likelihoods. We first rely on the following lemmas, which together prove that each
recurrent block of the HMRNN mimics matrix multiplication by diag(Ψyt), given some observation
yt at time t.
Lemma 3.1. Let unit h(t)1 (j) represent the jth unit of h
(t)
1 (j). If h
(t)
1 (j) ∈ [0, 1] for j ∈ {1, ..., k},
then h(t)3 = h
(t)
1 diag(Ψyt).
Proof. Let h(t)1 (j) and h
(t)
3 (j) represent the jth units of layer h
(t)
1 and h
(t)
3 , respectively. Showing
h
(t)
3 = h
(t)
1 diag(Ψyt) is equivalent to showing that h
(t)
3 (j) = Ψj,yth
(t)
1 (j) for j ∈ {1, .., k}.
To show this, recall that h(t)2 contains k×c units, which we index with a tuple (l,m) for l ∈ {1, . . . , c}
and m ∈ {1, . . . , k}. The connection matrix between h(t)1 and h(t)2 is [diag(Ψ1) . . . diag(Ψc)].
Thus, the connection between units h(t)1 (j) and h
(t)
2 (l,m) is Ψj,l when j = m, and equals 0
otherwise. Also recall that matrix Yt enters the model through a c-length input layer h
(t)
y , where
the jth unit is 1 when yt = j, and equals 0 otherwise. This layer is connected to h
(t)
2 by a c× (kc)
diagonal block matrix of c (1× k) row vectors of ones. Thus, the connection between the jth unit
of this input layer and unit (l,m) of h(t)2 is 1 when j = l, and equals 0 otherwise. Lastly, a bias of
−1 is added to all units in h(t)2 , which is then subject to a ReLu activation, resulting in the following
expression for each unit in h(t)2 :
h
(t)
2 (l,m) = ReLu(Ψm,l · h(t)1 (m) + h(t)y (l)− 1) (6)
Because h(t)y (l) is 1 when yt = l, and equals 0 otherwise, then if all units in h
(t)
1 are between 0 and
1, we have
h
(t)
2 (l,m) =
{
ReLu(Ψm,l · h(t)1 (m)) = Ψm,l · h(t)1 (m), j = yt,
ReLu(Ψm,l · h(t)1 (m)− 1) = 0, otherwise .
(7)
The connection matrix between h(t)2 and h
(t)
3 is a (kc)× k row-wise concatenation of k × k identity
matrices; thus, the connection between h(t)2 (l,m) and h
(t)
3 (j) is 1 if j = m, and 0 otherwise. Hence,
h
(t)
3 (j) =
c∑
j=0
h
(t)
2 (l, j) = Ψj,yt · h(t)1 (j). (8)
Thus, h(t)3 = h
(t)
1 diag(Ψyt).
Lemma 3.2. For all j ∈ {1, . . . , k} and t ∈ {0, . . . , T}, h(t)1 (j) ∈ [0, 1].
Proof. We show this by induction. We first assume that for some time t, 0 ≤ h(t)1 (j) ≤ 1 for all
j and
∑k
j=1 h
(t)
1 (j) ≤ 1. Given that h(t)3 (j) = Ψj,yt · h(t)1 (j) and 0 ≤ Ψi,j ≤ 1 for all i and j,
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then 0 ≤ h(t)3 (j) ≤ 1 for all j and
∑k
j=1 h
(t)
3 (j) ≤ 1. Since h(t+1)1 = h(t)3 P and 0 ≤ Pi,j ≤ 1
for all i and j, then 0 ≤ h(t+1)1 (j) ≤ 1 for all j and
∑k
j=1 h
(t+1)
1 (j) ≤ 1. Since h(0)1 = pi>, then
0 ≤ h(t)1 (j) ≤ 1 and
∑k
j=1 h
(t)
1 (j) ≤ 1 for t = 0, implying 0 ≤ h(t)1 (j) ≤ 1 for all j and t.
Theorem 3.1. An HMRNN with parameters pi (1× k stochastic vector), P (k× k stochastic matrix),
and Ψ (k×c stochastic matrix), and with layers defined as in equations (2-5), produces output neuron
o(T ) for sequence n ∈ {1, . . . , N} whose value is the negative log-likelihood of a corresponding
HMM as defined in equation (1).
Proof. Taken together, Lemmas 3.1 and 3.2 imply that h(t)3 = h
(t)
1 diag(Ψyt) for all t, while
h
(t+1)
1 = h
(t)
3 P . Thus, h
(t)
3 = h
(t−1)
3 (P · diag(Ψyt)) for t ∈ {1, . . . , T}. Thus, we can express
output neuron o(T ) recursively as o(T ) = − log(h(t)3 1k×1) = − log(h(0)3 (
∏T
t=1P ·diag(Ψyt))1k×1).
Lastly, for t = 0, h(0)1 = pi
>; thus, h(0)3 = pi
> · diag(Ψy0), and o(T ) = − log(pi> · diag(Ψy0) ·
(
∏T
t=1P · diag(Ψyt))1k×1), which is identical to the HMM likelihood from equation (1).
4 Experiments and Results
In this section, we compare HMRNNs to HMMs through computational experiments with synthetic
data and a case study of real-world clinical data from Alzheimer’s disease patients.
4.1 Empirical Validation of HMRNN
We confirm numerically that an HMRNN trained via gradient descent yields statistically similar
solutions to the Baum-Welch algorithm. We show this with synthetically-generated observation
sequences for which the true HMM parameters are known, allowing us to assess each algorithm’s
ability to recover the true model parameters.
We simulate two-state systems where each row of the transition and emission matrices is set to
either [0.05, 0.95] or [0.33, 0.67], for a total of 24 = 16 HMM’s. This allows us to test a “strong”
and “weak” case, respectively, for each probability/emission distribution (i.e., where the most likely
outcome is either near-certain, or only occurs with 2/3 probability). For each of the 16 HMMs, we
generate two 200-length synthetic observation sequences on which the Baum-Welch and HMRNN are
trained; one sequence for each HMM starts in state x0 = 0, while the other starts in state x0 = 1 (32
sequences in total). We train the HMM and HMRNN on 10 random initializations for each synthetic
sequence and select the best-performing (i.e., highest log-likelihood) parameter solution, yielding
32 finalized parameter solutions for comparison. Convergence is defined as all parameter estimates
ceasing to change by more than 0.0001. For analysis purposes, we define transition parameter
solutions as [min(P11,P22),max(P11,P22)]>, i.e., an ordered pair of the same-state transition
probabilities, which fully characterizes the 2× 2 transition probability matrix. We define emission
parameter solutions as [min(Ψ11,Ψ12),max(Ψ11,Ψ12)]>, i.e., an ordered pair of the probabilities
of observing yt(n) = 0, which fully characterizes the 2× 2 emission matrix.
Fig. 2 shows the log-likelihoods and parameter estimates for Baum-Welch and HMRNN parameter
solutions. Solutions across both models yield similar log-likelihoods (correlation r = 0.997), and
for 21 of the 32 model runs, transition and emission solutions differ by no more than 0.05 on
any parameter. A nonparametric multivariate test based on the energy distance ([21, 22]) finds
no significant differences between the Baum-Welch and HMRNN distributions of transition (p-
value = 0.40) or emission (p-value = 0.90) parameter solutions. The Baum-Welch and HMRNN
solutions also do not significantly differ in the Kullback-Leibler divergence between estimated and
ground truth transition distributions (Mann-Whitney U test, p-value = 0.29) or emission distributions
(Mann-Whitney U test, p-value = 0.27).
Moreover, Fig. 2(b) and Fig. 2(c) show that the medians of Baum-Welch and HMRNN parameter
solutions are close to the ground truth parameters, thus conforming empirically that the HMRNN
recovers the true parameters used to generate each observation sequence.
The median runtime for Baum-Welch across all model runs is 1.93 seconds, versus 64.28 seconds
for gradient descent with the HMRNN. This runtime difference reflects the fact that the HMRNN is
6
Figure 2: Comparison of HMM Baum-Welch and HMRNN gradient descent solutions for syn-
thetic data experiments. (a) Agreement of log-likelihoods between HMM/Baum-Welch and HM-
RNN/gradient descent. (b) Box plots of same-state transition parameters. Ground truth parameters
marked by crosses. (c) Box plots of emission parameters for Pr(y(n)t = 0). Ground truth parameters
marked by crosses.
fitting a very deep (600–layer) neural network, while the Baum-Welch algorithm is tailor-made for
the HMM data structure. Still, this emphasizes that any benefit of the HMRNN model should lie in
its ability to handle data structures inaccessible to the Baum-Welch algorithm, rather than its speed.
4.2 Alzheimer’s disease symptom progression data
We apply an HMRNN and augment it with other neural networks in a case study of Alzheimer’s
disease symptom progression. In doing so, we demonstrate how combining an HMRNN with other
neural networks can improve parameter fit and offer novel clinical interpretations.
We test our HMRNN on clinical data from n = 426 patients with mild cognitive impairment (MCI),
collected over the course of three (n = 91), four (n = 106), or five (n = 229) consecutive annual
clinical visits. Data was taken from the Alzheimer’s Disease Neuroimaging Initiative [23]. Given
MCI patients’ heightened risk of Alzheimer’s, modeling their symptom progression is of considerable
clinical interest [24, 25, 26]. We analyze patients’ level of functional independence based on the
Functional Activities Questionnaire (FAQ; [27]) and overall cognitive functioning based on the Mini
Mental Status Exam (MMSE; [28]). FAQ scores range from 0 to 30, with scores of 9− 30 indicating
impaired functioning and 0− 8 indicating normal functioning. MMSE scores range from 0 to 30,
with scores of 27− 30 indicating no cognitive impairment, 24− 26 indicating borderline cognitive
impairment, and 17− 23 indicating mild cognitive impairment [29, 30]. The proportion of scores
below 17 (1.2%) were insufficient for analysis of a separate diagnostic category, and these scores
were treated as scores of 17 (‘mild cognitive impairment’) for analysis purposes.
For FAQ analysis, we define the latent space as S = {0, 1}, with xt = 0 representing ‘normal
functioning’ and xt = 1 representing ‘impaired functioning.’ We define the observation space as
O = {0, 1}, with yt = 0 representing an FAQ score below 9 and yt = 1 representing an FAQ
score of 9 or higher. For MMSE analysis, we define the latent space as S = {0, 1, 2}, with xt = 0
representing ‘no cognitive impairment,’ xt = 1 representing ‘borderline cognitive impairment,’ and
xt = 2 representing ‘mild cognitive impairment.’ The observation space is O = {0, 1, 2}, with
yt = 0 representing an MMSE score of 27− 30, yt = 1 representing an MMSE score of 24− 26,
and yt = 2 representing an MMSE score of 17− 23.
To showcase the benefits of the HMRNN’s flexibility, we train three models each for the FAQ and
MMSE: a baseline HMM (using Baum-Welch), a baseline HMRNN, and an augmented HMRNN.
The baseline HMM and HMRNN simply learn the initial state probabilities, and the transition and
emission matrices from the n = 426 patient sequences. The augmented HMRNN showcases the
HMRNN’s flexibility through two substantive modifications. First, the initial state probabilities in the
augmented HMRNN are predicted from patients’ gender, age, degree of temporal lobe atrophy [31],
and amyloid-beta 42 levels (Aβ42, a relevant Alzheimer’s biomarker [32, 33]), using a single-layer
neural network. Second, at each time point, the probability of being in the most impaired state
(h(1)t (1) for FAQ, h
(1)
t (2) for MMSE) is used to predict concurrent scores on the Clinical Dementia
Rating (CDR, [34]), a global assessment of dementia severity, allowing another clinical metric to
inform estimation. We use a single connection and sigmoid activation to predict patients’ probability
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HMM HMRNN (baseline) HMRNN (augmented)
pi 0.909 0.091 0.912 0.088 0.946 0.054
P
0.918 0.082
0.030 0.970
0.923 0.076
0.014 0.986
0.918 0.082
0.007 0.993
Ψ
0.981 0.019
0.037 0.963
0.969 0.031
0.037 0.963
0.982 0.018
0.056 0.944
LL -905.32 -899.84 -861.71
Runtime 2.16 sec 2.73 sec 13.54 sec
Table 1: Results from Alzheimer’s disease case study (Functional Activities Questionnaire). Note that
pi indicates initial state probabilities, P indicates transition probability matrix, Ψ indicates emission
matrix, and LL indicates model log-likelihood. For transition probability matrices, element (i, j) is
the probability of transitioning from state i to state j. For emission matrices, element (i, j) is the
probability of making observation j from latent state i.
HMM HMRNN (baseline) HMRNN (augmented)
pi 0.727 0.271 0.002 0.730 0.269 0.001 0.667 0.333 0.000
P
0.898 0.080 0.022
0.059 0.630 0.311
0.000 0.016 0.984
0.900 0.085 0.015
0.077 0.617 0.305
0.002 0.027 0.971
0.970 0.028 0.002
0.006 0.667 0.327
0.000 0.003 0.997
Ψ
0.939 0.060 0.001
0.175 0.819 0.006
0.004 0.160 0.836
0.927 0.057 0.016
0.144 0.835 0.021
0.014 0.142 0.844
0.930 0.067 0.003
0.449 0.548 0.003
0.005 0.308 0.687
LL -1545.52 -1549.51 -1353.16
Runtime 2.89 sec 5.18 sec 15.24 sec
Table 2: Results from Alzheimer’s disease case study (Mini Mental Status Exam). Note that pi
indicates initial state probabilities, P indicates transition probability matrix, Ψ indicates emission
matrix, and LL indicates model log-likelihood. For transition probability matrices, element (i, j) is
the probability of transitioning from state i to state j. For emission matrices, element (i, j) is the
probability of making observation j from latent state i.
of receiving a CDR score above 0.5 (corresponding to ‘mild dementia’). We train all models using
a log-likelihood tolerance of 0.001% (we do not use parameter convergence since the number of
parameters differs across models).
FAQ model results appear in Table 1, and MMSE model results appear in Table 2. For both assess-
ments, augmenting the HMRNN with other neural networks improves fit and produces different
parameter interpretations. For FAQ data, the augmented HMRNN yields the highest starting probabil-
ity for functional impairment and the lowest probability of recovery this state. It also infers the highest
FAQ false negative rate – a 5.6% chance of impaired patients scoring as ‘normal’ (Ψ21 = 0.056,
Table 1). Thus, under the augmented HMRNN, patients are more likely to occupy the ‘functional
impairment’ state, and FAQ scores of 0− 8 are more likely to be attributed to false negatives (rather
than a ‘normal’ level of functioning). For MMSE data, the augmented HMRNN yields the lowest
transition probabilities between states and the lowest MMSE diagnostic accuracy. For instance, the
baseline HMM and HMRNN estimate at least an 80% chance of correctly identifying borderline and
mild cognitive impairment; that is, Ψ22 = 0.819 and Ψ33 = 0.836 for FAQ, and Ψ22 = 0.835 and
Ψ33 = 0.844 for MMSE (Table 2). These probabilities are (respectively) only 54.8% and 68.7%
under the HMRNN, suggesting that changes in scores are more likely attributable to testing error (as
opposed to true state changes) under the augmented HMRNN.
5 Discussion
We outline a flexible approach for HMM parameter estimation using neural networks. The HMRNN
produces statistically similar solutions to the Baum-Welch algorithm, yet can be combined with other
neural networks to improve parameter estimates. In our case study, the augmented HMRNN yields
higher log-likelihoods and different clinical interpretations than the baseline HMMs. For the FAQ, it
suggests a higher initial probability for ‘impaired’ functioning and a higher assessment false negative
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rate (5.6%), which, interestingly, is closer to other false negative rates for MCI screenings that rely on
the FAQ (7.1%, [35]), compared with the baseline HMMs. For the MMSE, the augmented HMRNN
estimates relatively poor diagnostic accuracy for the ‘borderline’ and ‘mild’ cognitive impairment
states, suggesting that fewer diagnostic categories might improve the MMSE’s utility (as supported
by existing MMSE research, e.g., [30]).
In addition to demonstrating the HMRNN’s utility in a practical setting, we also make a theoretical
contribution by formulating discrete-observation HMMs as a special case of RNNs and by proving
coincidence of likelihood functions between the two formulations. Unlike past approaches, our for-
mulation relies only on matrix multiplication and ReLu activations, and is designed to for generalized
use by optimizing for maximum likelihood, which is widely used for HMM training.
Future work may attempt to speed up the HMRNN approach to reach runtime parity with Baum-
Welch. It is worth noting that sequence lengths in healthcare are often considerably shorter than in
other domains that employ HMMs (e.g., speech analysis), and runtimes will likely remain reasonable
for many healthcare datasets. We also limited our practical case study to disease progression modeling,
while future work might explore HMRNN variants in other healthcare domains.
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